BR0010593A - Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv - Google Patents
Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hivInfo
- Publication number
- BR0010593A BR0010593A BR0010593-7A BR0010593A BR0010593A BR 0010593 A BR0010593 A BR 0010593A BR 0010593 A BR0010593 A BR 0010593A BR 0010593 A BR0010593 A BR 0010593A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- ccr5
- pegylated
- combination therapy
- interferon alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Patente de Invenção: "TERAPIA DE COMBINAçãO COM ANTAGONISTA DE CCR5-INTERFERON ALFA PEGUILADO PARA HIV". é divulgado o uso de um interferon-alfa peguilado e de um antagonista de CCR5, também em associação com pelo menos um de ribavirina, IL-2, IL-12, pentafusídeo sozinhos ou em combinação com uma terapia de droga anti-HIV-1, por exemplo, HAART, para a preparação de um medicamento para o tratamento de infecções por HIV-1 assim como de coinfecções por HIV-1 e HCV em pacientes adultos ou pediátricos que nunca receberam tratamento assim como nos que já receberam tratamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30489799A | 1999-05-04 | 1999-05-04 | |
PCT/US2000/011634 WO2000066141A2 (en) | 1999-05-04 | 2000-05-01 | Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0010593A true BR0010593A (pt) | 2002-02-13 |
Family
ID=23178462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0010593-7A BR0010593A (pt) | 1999-05-04 | 2000-05-01 | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1175224B1 (pt) |
JP (1) | JP2002543144A (pt) |
CN (1) | CN1349408A (pt) |
AR (1) | AR023824A1 (pt) |
AT (1) | ATE289516T1 (pt) |
AU (1) | AU776541B2 (pt) |
BR (1) | BR0010593A (pt) |
CA (1) | CA2365900A1 (pt) |
DE (1) | DE60018273T2 (pt) |
ES (1) | ES2238277T3 (pt) |
HK (1) | HK1039278B (pt) |
HU (1) | HUP0202734A3 (pt) |
MX (1) | MXPA01011116A (pt) |
MY (1) | MY127670A (pt) |
NO (1) | NO328679B1 (pt) |
NZ (1) | NZ514519A (pt) |
PE (1) | PE20010283A1 (pt) |
PT (1) | PT1175224E (pt) |
TW (1) | TWI289454B (pt) |
WO (1) | WO2000066141A2 (pt) |
ZA (1) | ZA200108870B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
JPWO2004092136A1 (ja) * | 2003-04-18 | 2006-07-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
US7498323B2 (en) | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
ATE374838T1 (de) | 2004-04-29 | 2007-10-15 | Hoffmann La Roche | Nukleotidsequenzvariation im gen ns5a als marker |
TWI400232B (zh) | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
BRPI0609251A2 (pt) * | 2005-02-23 | 2010-03-09 | Schering Corp | derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas |
JPWO2006129679A1 (ja) | 2005-05-31 | 2009-01-08 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
US8318931B2 (en) | 2005-10-28 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
JP5217438B2 (ja) | 2005-11-18 | 2013-06-19 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
AU2007225836A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
EP2055705A4 (en) | 2006-07-31 | 2014-08-20 | Ono Pharmaceutical Co | COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
US9187451B2 (en) | 2011-11-18 | 2015-11-17 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
CN105899219B (zh) | 2014-01-08 | 2021-08-13 | 免疫创新治疗有限公司 | 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗 |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
AU7473096A (en) * | 1995-11-02 | 1997-05-22 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
WO1998025617A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
-
2000
- 2000-05-01 HU HU0202734A patent/HUP0202734A3/hu unknown
- 2000-05-01 CA CA002365900A patent/CA2365900A1/en not_active Abandoned
- 2000-05-01 EP EP00928604A patent/EP1175224B1/en not_active Expired - Lifetime
- 2000-05-01 ES ES00928604T patent/ES2238277T3/es not_active Expired - Lifetime
- 2000-05-01 JP JP2000615025A patent/JP2002543144A/ja not_active Ceased
- 2000-05-01 BR BR0010593-7A patent/BR0010593A/pt not_active Application Discontinuation
- 2000-05-01 WO PCT/US2000/011634 patent/WO2000066141A2/en active IP Right Grant
- 2000-05-01 AU AU46815/00A patent/AU776541B2/en not_active Ceased
- 2000-05-01 PT PT00928604T patent/PT1175224E/pt unknown
- 2000-05-01 MX MXPA01011116A patent/MXPA01011116A/es active IP Right Grant
- 2000-05-01 CN CN00807116A patent/CN1349408A/zh active Pending
- 2000-05-01 NZ NZ514519A patent/NZ514519A/en not_active IP Right Cessation
- 2000-05-01 DE DE60018273T patent/DE60018273T2/de not_active Expired - Lifetime
- 2000-05-01 AT AT00928604T patent/ATE289516T1/de not_active IP Right Cessation
- 2000-05-02 AR ARP000102097A patent/AR023824A1/es unknown
- 2000-05-02 TW TW089108323A patent/TWI289454B/zh not_active IP Right Cessation
- 2000-05-02 PE PE2000000408A patent/PE20010283A1/es not_active Application Discontinuation
- 2000-05-02 MY MYPI20001893A patent/MY127670A/en unknown
-
2001
- 2001-10-26 ZA ZA200108870A patent/ZA200108870B/xx unknown
- 2001-11-02 NO NO20015367A patent/NO328679B1/no not_active IP Right Cessation
-
2002
- 2002-02-02 HK HK02100826.8A patent/HK1039278B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1039278A1 (en) | 2002-04-19 |
PE20010283A1 (es) | 2001-03-16 |
AU776541B2 (en) | 2004-09-16 |
AU4681500A (en) | 2000-11-17 |
NZ514519A (en) | 2003-07-25 |
HK1039278B (zh) | 2005-06-30 |
ATE289516T1 (de) | 2005-03-15 |
CN1349408A (zh) | 2002-05-15 |
MY127670A (en) | 2006-12-29 |
WO2000066141A3 (en) | 2001-02-08 |
TWI289454B (en) | 2007-11-11 |
HUP0202734A3 (en) | 2003-11-28 |
NO20015367D0 (no) | 2001-11-02 |
ES2238277T3 (es) | 2005-09-01 |
PT1175224E (pt) | 2005-07-29 |
JP2002543144A (ja) | 2002-12-17 |
CA2365900A1 (en) | 2000-11-09 |
NO328679B1 (no) | 2010-04-26 |
HUP0202734A2 (hu) | 2002-12-28 |
MXPA01011116A (es) | 2002-06-04 |
EP1175224B1 (en) | 2005-02-23 |
NO20015367L (no) | 2002-01-03 |
DE60018273D1 (de) | 2005-03-31 |
AR023824A1 (es) | 2002-09-04 |
ZA200108870B (en) | 2003-03-26 |
WO2000066141A2 (en) | 2000-11-09 |
EP1175224A2 (en) | 2002-01-30 |
DE60018273T2 (de) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0010593A (pt) | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv | |
BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
BR9910505A (pt) | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c | |
ES2251196T3 (es) | Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica. | |
PE119199A1 (es) | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica | |
BR9809425A (pt) | Conjugados alfa interferon-polietilenoglicol para terapia de infecção | |
BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
BR0008840A (pt) | Derivados de camptotecina tendo atividade antitumoral | |
WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
BRPI0108435B8 (pt) | formulação e uso de entecavir de baixa dose | |
BR9810745A (pt) | Derivados de benzimidazol | |
BR0108997A (pt) | Terapia imune adjuvante para hiv | |
BR9808303A (pt) | O uso de levobupivacaìna na cirurgia facial | |
PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
PT91524A (pt) | Processo de preparacao de um medicamento a base de fraccoes e/ou fragmentos de heparina | |
BR9807473A (pt) | Tratamentos de doença relacionados à citocina | |
BR9915644A (pt) | Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus | |
HK1056838A1 (en) | Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus. | |
BR0311696A (pt) | Tratamento de hepatite c na população asiática com interferon-beta subcutâneo | |
WO2000051631A3 (en) | Pegylated alpha interferon for hiv therapy | |
BR9713514A (pt) | Novo uso de creatina | |
BRPI0409711A (pt) | tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina | |
ECSP003462A (es) | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k) | |
WO2000043014A8 (en) | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections | |
BR9812466A (pt) | Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM ART. 24, ART. 8O COMBINADO COM ART. 11, ART. 10, ART. 25 E ART. 6 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |